FDA approves Reclast to prevent osteoporosis in postmenopausal women with convenient less frequent dosing
Links shared publicly online about this topic.
- 2,002total visits
FDA approves Reclast to prevent osteoporosis in postmenopausal women with convenient less frequent dosing
Basel, June 1, 2009 - Reclast (zoledronic acid 5 mg) Injection[*] has been approved by the US Food and Drug Administration (FDA) as the first and only therapy to prevent postmenopausal osteoporosis for two years with a single dose[1]. Reclast, or Aclasta as it is known outside the US, is already approved in more than 80 countries including the US and EU as a once-yearly infusion for the treatment of postmenopausal osteoporosis[1],[4].
View full resource at novartis.com
Tags: Osteoporosis, Drug, Women's Health, FDA
Most Recently Shared on June 1, 2009 at 5:36 am By:
FDA approves Reclast® to prevent osteoporosis in postmenopausal women with convenient less frequent dosing: http://twurl.nl/po8fan
Advertisement
